Canaccord Genuity Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1057

Benzinga · 1d ago
Canaccord Genuity analyst John Newman maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $850 to $1057.